MorphoSys AG nearly doubled revenue in the third quarter as it reaped the first benefits from its newly launched cancer treatment Monjuvi (tafasitamab). Revenue for the quarter increased to €22 million, up from €12.5 million a year earlier, of which €4.4 million represented sales of Monjuvi, an antibody therapeutic approved by the US Food and Drug Administration on 31 July. Monjuvi is to be used for the treatment, in combination with lenalidomide, of patients with refractory diffuse large B-cell lymphoma. It is MorphoSys’ first proprietary product to reach the market.
